Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials

Abstract

BackgroundWith the appearance of oral direct-acting antivirals (DAAs), the field of hepatitis C virus (HCV) treatment has been dramatically changed. This evolution makes possible for all oral treatments to be available for the treatment of HCV-infected patients. The aims of this review were to report the efficacy and safety of sofosbuvir (SOF)-based regimens for the treatment of patients with chronic HCV infection and to provide our clinical perspectives on these regimens.MethodsA literature search of clinical studies published in PubMed and posted on ClinicalTrials.gov website was performed to identify studies evaluating the efficacy or safety of SOF-containing treatment regimens.ResultsA total of 23 clinical trials were examined in the review. The evaluated SOF-based regimens are as follows: SOF/daclatasvir (DCV) ± ribavirin (RBV), SOF/ledipasvir (LDV) ± RBV, SOF/simeprevir (SMV), SOF/velpatasvir (VEL) ± RBV, and SOF/RBV ± peginterferon (peg-IFN). These SOF-based regimens were at least effective and safe for HCV-infected patients with or without cirrhosis. The SOF/VEL ± RBV regimen, a pan-genotypic DAA regimen, was effective for the treatment of patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection. The 24-week SOF/RBV regimen was as effective as the 12-week SOF/RBV/peg-IFN regimen. Patients with HCV genotype 3 infection could have benefits from the use of the 24-week SOF/RBV regimen. For cirrhotic patients with HCV genotype 3 infection, the 12-week SOF/RBV/peg-IFN regimen could be considered as an alternative treatment option when access to SOF-based regimens with other DAAs is limited. In the included studies, significant adverse events due to SOF-based regimens were not reported.ConclusionThe clinical trials suggest that SOF-based treatment regimens for HCV-infected patients with or without cirrhosis can be at least effective and safe patient-convenient medications. However, it is necessary to monitor HCV-infected patients, since rare adverse events, drug–drug interactions, and drug–disease interactions can occur in real clinical settings.

Tolerability and effectiveness of generic direct‐acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients

“…Male gender, platelet count and INR were proved as predictors of SVR. We reported only 0.6% non‐response and 0.3% relapse rates, which highlights the efficacy of generic DAAs used in our study when compared to data published about original brands …”

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis

“…DCV‐TRIO, like other oral DAA, showed a high safety profile in the form of minimal serious AEs and discontinuation due to AEs. The most serious AEs reported with other DAA regimens were not related to the treatment or the dosage and most of reported AEs were grade 1 and 2 . The most common AEs, including headache, fatigue, diarrhea, and nausea, showed no difference regarding the dosage or duration of the therapy.…”

Twenty Years of Hepatitis C in the Treviso District (Local Health Unit 2): Treatments, Clinical Management and Cost Analysis

“…Considerato il notevole impegno economico necessario per garantire le cure ai pazienti affetti da HCV, si è reso necessario analizzare l'efficacia dei nuovi DAA, intesa come raggiungimento della SVR in condizioni di real practice: i farmaci erogati negli anni 2015-2016 hanno dimostrato un'efficacia migliore a quella espressa dai clinical trial, con performance superiori agli studi registrativi riportati nel riassunto caratteristiche del prodotto (RCP). 24 L'analisi economica dei costi globali della patologia è stata effettuata quantificando la durata media di ogni intervallo di fibrosi, dall'origine dell'infezione agli ultimi stadi della malattia. Limite di questa analisi è il criterio di scelta per la stadiazione della popolazione: non tutti i pazienti hanno avuto una registrazione della progressione della fibrosi, inoltre l'indagine clinica non è sempre puntuale e fornisce esiti corretti.…”